Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 07:05 ET
|
Apellis Pharmaceuticals, Inc.
Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 26, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences: TD...
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 4 new employees with a grant...
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
January 26, 2024 07:06 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European...
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
January 08, 2024 09:00 ET
|
Apellis Pharmaceuticals, Inc.
Approximately $114 million in preliminary fourth quarter SYFOVRE® revenue as strong launch continuesApproximately $24 million in preliminary fourth quarter EMPAVELI® revenue WALTHAM, Mass., Jan. ...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 2 new employees with a grant...
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on...
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
December 28, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite...
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
December 14, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for...